Does the Type of BCR/ABL Junction Predict the Survival of Patients with Ph¹-Positive Chronic Myeloid Leukemia?

References

• Tura S., Baccarani M., Zaccaria A. Chronic myeloid leukemia. Haematologica 1986; 71: 169–176
   PubMedGoogle Scholar
• Rowley J. D. A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature 1973; 243: 290–293
   PubMed Web of Science ®Google Scholar
• Talpaz M., Kantarjian H., Kurzrock R., Trujillo J. M. Interferon-alpha produces sustained cytogenetic responses in chronic myelogenous leukemia. Ann. Int. Med. 1991; 114: 532–538
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Treatment of Ph-positive chronic myeloid leukemia with a-Interferon (Roferon-A). The Italian Cooperative Study Group experience. Leukemia and Lymphoma 1993; 11(Suppl. 1)153–157
   Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Progress in treatment of chronic myeloid leukemia: interferon versus conventional chemotherapy. N. Engl. J. Med. 1994; 330: 820–825
   PubMed Web of Science ®Google Scholar
• Tura S., Baccarani M., Corbelli G., The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Staging of chronic myeloid leukemia. Br. J. Haematol. 1981; 47: 105–109
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Keating M. J., Smith T. L., Talpaz M., McCredie K. B. Proposal for a simple synthesis prognostic staging system in chronic myelogenous leukemia. Am. J. Med. 1990; 61: 1441–1446
   Google Scholar
• Sokal J. E., Cox E. B., Baccarani M., et al. Prognostic discrimination in “good risk” chronic granulocytic leukemia. Blood 1984; 63: 789–799
   PubMed Web of Science ®Google Scholar
• Heisterkamp N., Stam K., Groffen J., de Klein A., Grosveld G. Structural organization of the bcr gene and its role in the Phi translocation. Nature 1985; 315: 758–761
   PubMed Web of Science ®Google Scholar
• Groffen J., Stephenson J. R., Heisterkamp N., de Klein A., Bartram C. R., Grosveld G. Philadelphia chromosome breakpoints are located within a limited region, bcr, on chromosome 22. Cell 1984; 36: 93–99
   PubMed Web of Science ®Google Scholar
• Kurzrock R., Gutterman J. U., Talpaz M. The molecular genetics of Philadelphia chromosome positive leu-kemias. N. Engl. J. Med. 1988; 319: 990–992
   PubMed Web of Science ®Google Scholar
• Chan L. C., Karhi K. K., Rayter S. I., Heisterkamp N., Eridani S., Powles R., Lawler S. D., Groffen J., Foulkes J. G., Greaves M. F., Wiedemann L. M. A novel abl protein expressed in Philadelphia chromosome positive acute lymphoblastic leukemia. Nature 1987; 325: 635–637
   PubMed Web of Science ®Google Scholar
• Ben Neriah Y., Daley G. Q., Mes-Masson A. M., Witte O. N., Baltimore D. The chronic myelogenous leukemia specific p210 protein is the product of the bcr/abl hybrid gene. Science 1986; 233: 212–214
   PubMed Web of Science ®Google Scholar
• Mills K. I., MacKenzie E. D., Birnie G. D. The site of the breakpoint within the bcr is a prognostic factor in Philadelphia-positive CML patients. Blood 1988; 72: 1237–1241
   PubMed Web of Science ®Google Scholar
• Shaefer-Rego K., Dudek M., Popenoe D., Arlin Z., Mears J. G., Bank A., Leibowitz D. CML patients in blast crisis have breakpoints localized to a specific region of the BCR. Blood 1987; 70: 448–455
   PubMed Web of Science ®Google Scholar
• Eisenberg A., Silver R., Soper L., Arlin Z., Coleman M., Bernhardt B., Benn P. The location of breakpoints within the breakpoint cluster region (bcr) of chromosome 22 in chronic myeloid leukemia. Leukemia 1988; 2: 642–647
   PubMed Web of Science ®Google Scholar
• Shtalrid M., Talpaz M., Kurzrock R., Kantarjian H., Tru-Jillo J., Gutterman J., Yoffe G., Blick M. Analysis of breakpoints within the bcr gene and their correlation with the clinical course of Philadelphia-positive chronic myelogenous leukemia. Blood 1988; 72: 485–490
   PubMed Web of Science ®Google Scholar
• Dreazen O., Berman M., Gale R. P. Molecular abnormalities of bcr and c-abl in chronic myelogenous leukemia associated with a long chronic phase. Blood 1988; 71: 797–799
   PubMed Web of Science ®Google Scholar
• Przepiorka D. Breakpoint zone of bcr in chronic myelogenous leukemia does not correlate with disease phase or prognosis. Cancer Genet. Cytogenet. 1988; 36: 117–122
   PubMed Web of Science ®Google Scholar
• Morris S. W., Daniel L., Ahmed C. M. I., Elias A., Leibowitz P. Relationship of bcr breakpoint to chronic phase duration, survival and blast crisis lineage in chronic myelogenous leukemia patients presenting in early chronic phase. Blood 1990; 75: 2035–2041
   PubMed Web of Science ®Google Scholar
• Tien H. F., Wang C. H., Chen Y. C., Shen M. C., Wu H. S., Lee F. Y., Chuang S. M., Liu C. H. Chromosome and bcr rearrangement in chronic myelogenous leukaemia and their correlation with clinical states and prognosis of the disease. Br. J. Haemat. 1990; 75: 469–475
   PubMed Web of Science ®Google Scholar
• Jaubert J., Martiat P., Dowding C., Ifrah N., Goldman J. M. The position of the M-BCR breakpoint does not predict the duration of the chronic phase of survival in chronic myeloid leukaemia. Br. J. Haemat. 1990; 74: 30–35
   PubMed Web of Science ®Google Scholar
• Zaccaria A., Martinelli G., Buzzi M., Zuffa E., Zamagni D., Testoni N., Guerrasio A., Saglio G., Tura S. M-BCR breakpoint location does not predict survival in Philadelphia chromosome-positive chronic myeloid leukemia. Haematologica 1992; 77: 16–20
   PubMedGoogle Scholar
• Opalka B., Wandl U., Beer U., Roggenbuck U., Kloke O., Niederle N. Breakpoint localization within the M-BCR and clinical course do not correlate in patients with chronic myelogenous leukemia undergoing alfa interferon therapy. Leukemia 1991; 5: 452–456
   PubMed Web of Science ®Google Scholar
• Zaccaria A., Martinelli G., Buzzi M., et al. The type of BCR/ABL junction does not predict the survival of patients with Ph'-positive chronic myeloid leukaemia. Br. J. Haematol. 1993; 84: 265–268
   PubMed Web of Science ®Google Scholar
• Southern E. D. Detection of specific sequences among DNA fragments separated by gel electrophoresis. J. Mol. Biol. 1975; 98: 503–517
   PubMed Web of Science ®Google Scholar
• Mills K., Hynds S. A., Burnett A. K., MacKenzie E. D., Birnie G. D. Further evidence that the site of the breakpoint in the major breakpoint cluster region (M-bcr) may be a prognostic indicator. Leukemia 1989; 3: 837–840
   PubMed Web of Science ®Google Scholar
• Mills K. The relationship between the location of the breakpoint within the M-BCR and clinical parameters. Leukemia and Lymphoma 1993; 11(Suppl. 1)73–79
   PubMed Web of Science ®Google Scholar
• Benn P., Birnie G. D., MacKenzie E., Mills K. I. bcr breakpoint and prognosis of chronic phase chronic myeloid leukemia. Blood 1990; 76: 2637
   PubMed Web of Science ®Google Scholar
• Mills K. I., Benn P., Birnie G. D. Does the breakpoint within the major breakpoint cluster region (M-bcr) influence the duration of the chronic phase in chronic myeloid leukemia? An analytical comparison of current literature. Blood 1991; 78: 1155–1161
   PubMed Web of Science ®Google Scholar
• The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Karyotypic conversion by Interferon as preparative treatment for autologous BMT in Ph positive CML. Leukemia and Lymphoma 1993; 11(Suppl. 1)277–280
   PubMedGoogle Scholar
• Taylor K., Elliott S. L., Taylor D., et al. 5′ breakpoint in the major breakpoint cluster region (M-BCR) predicts for major cytogenetic response to alpha-Interferon (a-IFN) therapy in early chronic phase” chronic myeloid leukemia. Blood 1992; 80(Suppl. 1)210a, abstract 830
   Google Scholar
• Lee M., Kantarjian H., Talpaz M., Deisseroth A., Freir-Eich E., Trujillo J., Stass S. Association of the responsiveness to interferon a (IFN a therapy with the BCR/ ABL splicing patterns in Philadelphia chromosome (Ph)-pos-itive chronic myelogenous leukemia (CML). Blood 1992; 80(Suppl. 1)210a, abstract 831
   Google Scholar
• Martinelli G., Chiamenti A., Gaspanni P., Pignatti P. F., Ambrosetti A., Zaccaria A., Buzzi M., Testoni N., Tura S., Guerrasio A., et al. BCR breakpoint subregions and blast crisis lineage in CML patients. Blood 1992; 79: 838–839
   PubMed Web of Science ®Google Scholar
• Dowding G., Guo A. P., Maisin D., Gordon M. Y., Goldman J. M. The effect of interferon-a on the proliferation of CML progenitor cells in vitro are not related to the precise position of the M-BCR breakpoint. Br. J. Haematol. 1991; 77: 165–171
   PubMed Web of Science ®Google Scholar
• Van Denderen J., Hacken T., Berendes P., Van Ewijk W. Detection of tumor-specific antigens in Philadelphia chromosome positive leukemias. Leukemia and Lymphoma 1993; 11(Suppl. 1)29–32
   PubMed Web of Science ®Google Scholar
• Chen W., Peace D. J., Rovira D. K., Sheng-Guo Y., Cheever M. A. T-cell immunity to the joining region of p210BCR-ABL protein. Proc. Natl. Acad. Sci. USA 1992; 89: 1468–1472
   PubMed Web of Science ®Google Scholar
• Brown J. H., Jardetzky T. S., Gorga J. C., Stern L. J., Urban R. J., Strominger J. L., Wiley D. C. Three dimensional structure of the human class II histocompatibility antigen HLA-DR1. Nature 1993; 364: 33–39
   PubMed Web of Science ®Google Scholar